Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
about
Synthetic lethality and cancer.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer.Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on the unfolded-protein response, calcium homeostasis, and redox balance.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.Proteomic Analysis of the Downstream Signaling Network of PARP1.Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2.Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib.A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.Dual Inhibitors of PARPs and ROCKs
P2860
Q38709651-0B2BB00C-3486-4A94-A849-F7430876E1AAQ38954348-322EF7E0-9BE0-4172-8F42-90969D720DA7Q40180908-CF66ADD0-9D37-492A-8677-149B794D0E89Q41592297-30BCED1D-FCAA-487E-847B-7ED95A80A850Q47096483-AC0C1506-DE79-48B9-9492-7BA107C5C999Q47236958-11FA0299-40F8-4A8D-9232-831C2B266BA2Q47285613-5B565AC3-CA0B-4370-B6E0-6760418EFF49Q47761787-4F427F33-0B2D-4E55-A833-7E3F3F16916BQ48164214-E3684CF7-F083-4BCE-9B7E-6E82955AEDD6Q48254511-FF18CC13-FE9A-4C40-9F4E-9D65F2D34799Q49180002-B7189498-7C54-4679-9888-A4753CED7203Q52639510-FC51FA83-D82A-4C95-96F6-C59C727E85C8Q53694059-2805F7FB-5A2A-42D2-9FFC-7AC48B28279DQ58581240-1B64B06F-2245-45ED-AF77-E82C9EA8FD47
P2860
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Proteome-wide Profiling of Cli ...... nd-Specific Secondary Targets.
@en
type
label
Proteome-wide Profiling of Cli ...... nd-Specific Secondary Targets.
@en
prefLabel
Proteome-wide Profiling of Cli ...... nd-Specific Secondary Targets.
@en
P2093
P2860
P1476
Proteome-wide Profiling of Cli ...... nd-Specific Secondary Targets.
@en
P2093
Caius Radu
Claire E Knezevic
Eric B Haura
Gabriela Wright
Harshani R Lawrence
January M Watters
John M Koomen
Lily L Remsing Rix
Woosuk Kim
P2860
P304
P356
10.1016/J.CHEMBIOL.2016.10.011
P577
2016-11-09T00:00:00Z